




PHARMACEUTICAL 2018

MELINTA THERAPEUTICS INC. NEW
Rank 207 of 342





RealRate

PHARMACEUTICAL 2018

MELINTA THERAPEUTICS INC. NEW Rank 207 of 342

The relative strengths and weaknesses of MELINTA THERAPEUTICS INC. NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MELINTA THERAPEUTICS INC. NEW compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 30% points. The greatest weakness of MELINTA THERAPEUTICS INC. NEW is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 53%, being 7.2% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	149,764
Cost of Goods Sold	0
Intangible Assets	7,500
Liabilities, Current	31,730
Liabilities, Non-Current	56,207
Other Assets	1,413
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	20,020
Other Revenues	33,864
Property and Equipment	1,596
Research and Development	49,475
Selling, General and Administrative Expense	63,325

Output Variable	Value in 1000 USD
Assets	160,273
Liabilities	87,937
Expenses	112,800
Revenues	33,864
Stockholders Equity	72,336
Net Income	-58,916
Comprehensive Net Income	-58,916
Economic Capital Ratio	53%